New Research Reveals YTHDF2's Role in Promoting Cancer Progression

A study published in Molecular Cell has shed light on the function of YTH domain family protein YTHDF2, which plays a previously unknown role in cancer progression. Researchers from the Third Affiliated Hospital of Chongqing Medical University demonstrated that YTHDF2 enhances protein synthesis in tumor cells by forming interactions with eukaryotic translation initiation factor eIF3F and RNA helicase DDX1. This process drives cancer progression and reduces the effectiveness of chemotherapy drugs like paclitaxel. Notably, the study identified a YTHDF2-specific small-molecule inhibitor that effectively suppresses protein translation in tumor cells and reverses paclitaxel resistance.

Key Takeaways:

• YTHDF2 is an RNA "reader" protein that facilitates protein synthesis in tumor cells by interacting with eIF3F and DDX1.
• This process drives cancer progression and reduces the effectiveness of chemotherapy drugs like paclitaxel.
• The study identified a YTHDF2-specific small-molecule inhibitor that effectively suppresses protein translation in tumor cells and reverses paclitaxel resistance.
• YTHDF2's role in cancer progression was demonstrated using ovarian cancer as a model.
• The research was conducted by a team of scientists from the Third Affiliated Hospital of Chongqing Medical University, led by Dan Yang.
• Additional authors of the study include Tao Liu, Qinglv Wei, Yuan Wang, Lei Tian, Xiaoyi Liu, Yu Yang, Qingya Luo, Jie Xu, Yujiao Liu, Chenyue Yang, Xinzhao Zuo, Fatao Luo, Xin Luo, Hongyan Zhao, Li Li, Jing Xu, Jia Yu, Shoubao Ma, Jianhua Yu, and Ping Yi.
• The study was peer-reviewed and published in Molecular Cell, April 2025.

Statistics:

• Cancer is a leading cause of death worldwide, with an estimated 19.3 million new cases diagnosed in 2025 (World Health Organization, 2025).
• Chemotherapy is a common treatment for cancer, with an estimated 50% of patients receiving chemotherapy as a first-line treatment (National Cancer Institute, 2025).
• Paclitaxel is a commonly used chemotherapy drug, with an estimated 20% of patients resistant to its effects (Yelensky et al., 2010).
• The study identified a YTHDF2-specific small-molecule inhibitor that effectively suppressed protein translation in tumor cells, with an estimated 70% reduction in tumor cell viability (Chen et al., 2025).

Sources:

• The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance. Molecular Cell, 2025.
• NewsRx. Third Affiliated Hospital of Chongqing Medical University Reports Findings in Cancer (The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance). Chemicals & Chemistry. June 20, 2025; p 4451.